Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the american academy of neurology

Neurology

Volumn 78, Issue 13, 2012, Pages 1009-1015

  Patwa, H S ^a   Chaudhry, V ^b   Katzberg, H ^c   Rae Grant, A D ^d   So, Y T ^e  

^a YALE UNIVERSITY   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d LERNER RESEARCH INSTITUTE   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; PREDNISONE;

ANOREXIA; ARTHRALGIA; ARTICLE; ASEPTIC MENINGITIS; ASTHENIA; CHILL; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); DERMATOMYOSITIS; DIABETIC NEUROPATHY; DIABETIC RADICULOPLEXONEUROPATHY; DIZZINESS; DRUG FEVER; DRUG TREATMENT FAILURE; EATON LAMBERT SYNDROME; EMBASE; EVIDENCE BASED PRACTICE; GROUPS BY AGE; GUILLAIN BARRE SYNDROME; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOLOGULIN M PARAPROTEIN ASSOCIATED NEUROPATHY; IMMUNOTHERAPY; INCLUSION BODY MYOSITIS; KIDNEY FAILURE; LOADING DRUG DOSE; MALAISE; MEDLINE; MOTOR NEUROPATHY; MYASTHENIA GRAVIS; NAUSEA; NEUROMUSCULAR DISEASE; OPTIMAL DRUG DOSE; PLASMAPHERESIS; POLYMYOSITIS; POSTPOLIOMYELITIS SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; URTICARIA;

EID: 84860815645     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824de293     Document Type: Article

References (36)

1. Cortese I, Chaudhry V, So YT, Cantor F, Cornblath DR, Rae-Grant A. Evidence-based guideline update: Plasmapheresis in neurological disorders: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;76: 294-300.
2. Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: A randomized trial. Pediatrics 2005;116:8-14.
3. Gurses N, Uysal S, Cetinkaya F, Ilek I, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain-Barré syndrome. Scand J Infect Dis 1995;27: 241-243.
4. van der Meche FG, Schmitz PI; for Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
5. Hughes RAC, Swan AV; for Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349:225-230. (Pubitemid 27050987)
6. Bril V, Ilse WK, Pearce R, et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
7. Nomura T, Hamaguchi K, Hattori T, et al. A randomized controlled trial comparing intravenous immunoglobulin and plasmapheresis in Guillain-Barré syndrome. Neurol Therapeutics 2000;18:69-81.
8. Diener H-C, Haupt WF, Kloss TM, et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré Syndrome. Eur Neurol 2001;46:107-109. (Pubitemid 32786141)
9. van Koningsveld R, Schmitz PI, Meche FG, Visser LH, Meulstee J, van Doorn PA. Effect of methylprednisolone when added to standard treatment with intravenous im-munoglobulin for Guillain-Barré syndrome: Randomised trial. Lancet 2004;363:192-196. (Pubitemid 38114716)
10. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; for French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71:235-238. (Pubitemid 32675152)
11. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial. Lancet Neurol 2008;7:136-144.
12. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56:445-449. (Pubitemid 32172866)
13. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebocontrolled, cross-over study. Brain 1996;119:1067-1077. (Pubitemid 26300709)
14. Vermeulen M, van Doorn PA, Brand A, et al. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39. (Pubitemid 23062977)
15. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201. (Pubitemid 32738144)
16. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: A randomized controlled trial. Neurology 2007;68:837-841. (Pubitemid 46568535)
17. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-552.
18. Ronager J, Ravnborg M, Hermansen I, Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25:967-973. (Pubitemid 34107305)
19. Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical Study Group. Ann Neurol 1997;41:789-796. (Pubitemid 27249184)
20. Leger JM, Chassande B, Musset L, Meininger V, Bouche P, Baumann N. Intravenous immunoglobulin therapy in multifocal motor neuropathy: A double-blind, placebocontrolled study. Brain 2001;124:145-153. (Pubitemid 32055996)
21. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg: Randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
22. Azulay JP, Blin O, Pouget J, et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 1994;44:429-432.
23. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370-1377. (Pubitemid 35217657)
24. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40:792-795. (Pubitemid 26415192)
25. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000. (Pubitemid 24015043)
26. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997;48:712-716. (Pubitemid 27120112)
27. Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56:323-327. (Pubitemid 32144142)
28. Walter MC, Lochmuller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: A double-blind, placebo-controlled study. J Neurol 2000;247:22-28. (Pubitemid 30162508)
29. Gonzalez H, Sunnerhagen KS, Sjoberg I, et al. Intravenous immunoglobulin for post-polio syndrome: A randomised controlled trial. Lancet Neurol 2006;5:493-500.
30. Farbu E, Rekand T, Vik-Mo E, et al. Post-polio patients treated with intravenous immunoglobulin: A doubleblinded randomized controlled pilot study. Eur J Neurol 2007;14:60-65. (Pubitemid 46088038)
31. Bain PG, Motomura M, Newsome-Davis J, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-683.
32. Steinberger B, Coleman TA. Multiple complications of IVIg therapy in a patient with Guillain-Barré syndrome. Am J Hematol 2001;67:59. (Pubitemid 32336709)
33. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: Case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 2000;75:83-85. (Pubitemid 30035798)
34. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256:339.
35. Van Den Berg LH, Kerkhoff H, Oey PL, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995;59:248-252.
36. Mariette X, Chastang C, Louboutin J-P, et al. A randomized clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 1997;63:28-34. (Pubitemid 27317357)